Viewing Study NCT06677892


Ignite Creation Date: 2025-12-24 @ 3:07 PM
Ignite Modification Date: 2025-12-24 @ 3:07 PM
Study NCT ID: NCT06677892
Status: RECRUITING
Last Update Posted: 2025-09-09
First Post: 2024-11-06
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Sponsor: Takeda
Organization:

Study Overview

Official Title: Prospective, Non-interventional Study to Describe The Use of Maribavir and Its Effectiveness in Patients With Post-transplant Cytomegalovirus Infection/Disease in Line With Belgian Reimbursement Conditions (The MARIBEL Study)
Status: RECRUITING
Status Verified Date: 2025-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MARIBEL
Brief Summary: Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant.

The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria.

During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: